Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04160910 · ClinicalTrials.gov registry record · Phase 2
5HTP Regulation Of Asthma In Children
A Phase 2 study of Mild or Moderate Asthma With Allergic Sensitization, sponsored by Indiana University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04160910 is a Phase 2 study of Mild or Moderate Asthma With Allergic Sensitization that is actively recruiting participants, run by Indiana University. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04160910, a Phase 2 study of Mild or Moderate Asthma With Allergic Sensitization, is actively recruiting participants, sponsored by Indiana University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn more about if taking a supplement called 5-hydroxytryptophan (5HTP) can improve breathing and anxiety symptoms related to asthma. To help learn more subjects will either be assigned to a group that is taking the supplement (5HTP) or a group that is taking a placebo. This will be decided randomly. Later in the study subjects will crossover to the other group.There are 5 study visits over the course of about 12 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG 5-Hydroxytryptophan
Study Locations (1)
Indiana
- Indiana University - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-02-11 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04160910
The ClinicalTrials.gov registry entry for NCT04160910 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mild or Moderate Asthma With Allergic Sensitization appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04160910 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT04160910 about?
NCT04160910 is a clinical study titled "5HTP Regulation Of Asthma In Children". The purpose of this study is to learn more about if taking a supplement called 5-hydroxytryptophan (5HTP) can improve breathing and anxiety symptoms related to asthma. To help learn more subjects will either be assigned to a group that is taking the supplement (5HTP) or a group that is taking a plac...
What is the current status of trial NCT04160910?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2021-02-11. Estimated completion is 2026-06-30.
What conditions does trial NCT04160910 study?
This clinical trial studies the following conditions: Mild or Moderate Asthma With Allergic Sensitization.
What interventions are being tested in trial NCT04160910?
The interventions under investigation include: Placebo (DRUG), 5-Hydroxytryptophan (DRUG).
Who is sponsoring clinical trial NCT04160910?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04160910 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.